iStent Infinite and iDose TR for Management of Moderate to Severe Primary Open Angle Glaucoma Are a Safe and Effective Alternative to Filtering Surgery for IOP Reduction in Patients With Medically Uncontrolled Glaucoma. (POAG)
Status: Recruiting
Location: See location...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Moderate to severe open angle glaucoma (including POAG, PG, and PXG)
• Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9
• Visual acuity HM or better
• VF MD -6dB or worse
• Failed medical therapy and/or laser treatment
• Incisional glaucoma surgery contemplated as next intervention
• Phakic or pseudophakic
Locations
United States
Pennsylvania
Wills Eye Hosital Glaucoma Dept.
RECRUITING
Philadelphia
Contact Information
Primary
Meskerem Divers
mdivers@willseye.org
215-825-4712
Backup
Jeanne L Molineaux, COA
jmolineaux@willseye.org
215-825-4713
Time Frame
Start Date: 2026-01-05
Estimated Completion Date: 2031-12-31
Participants
Target number of participants: 20
Treatments
Experimental: Surgery for patients with medically uncontrolled POAG
surgery using combined minimally invasive surgical iStent infinite trabecular micro-bypass systme model iS3 and drug depot iDose TR (Travoprost Intracameral Implant) 75mcg
Related Therapeutic Areas
Sponsors
Leads: Jonathon Myers
Collaborators: Glaukos Corporation